Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011570 (depression)
 172,036 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The objective was to determine in infants with perinatal depression whether the relative concentrations of N-acetylaspartate and lactate in the neonatal period are associated with (1) neurodevelopmental outcome at 30 mo of age or (2) deterioration in outcome from age 12 to 30 mo; and to determine whether socioeconomic factors are associated with deterioration in outcome. Thirty-seven term neonates were prospectively studied with single-voxel proton magnetic resonance spectroscopy of the basal nuclei and intervascular boundary zones. Thirty-month outcomes were classified as normal [if Mental Development Index of the Bayley Scales of Infant Development (MDI) >85 and neuromotor scores (NMS) <3; n = 15], abnormal [if MDI <or=85 and/or NMS >or=3 at 12 and 30 mo; n = 11], or deteriorated [if normal at 12 mo and abnormal at 30 mo (MDI <or=85 or NMS >or=3); n = 11]. Thirty percent (11/37) of our cohort deteriorated between 12 and 30 mo. N-acetylaspartate/choline decreased across the groups ordered as normal, deteriorated, and abnormal [in basal nuclei (p <or= 0.001) and intervascular boundary zones (p = 0.04)], but was not different between the normal and deteriorated groups (p = 0.08). Lactate/choline similarly increased across the groups [in basal nuclei (p = 0.01) and intervascular boundary zones (p = 0.05)]. The odds of deterioration, if normal at 12 mo, increased by a factor of 5.1 (95% confidence interval: 1.3-19.8) with each decrease in one of four household income strata. Infants with perinatal depression are at high risk of developmental deterioration between 12 and 30 mo of age, particularly if in a lower income home or with intermediate values of cerebral metabolites on neonatal proton magnetic resonance spectroscopy.
 ...
PMID:Predictors of 30-month outcome after perinatal depression: role of proton MRS and socioeconomic factors. 1208 50

The first step in initiating treatment is to establish the diagnosis, confirming MDD and being careful to rule out BPAD and comorbid anxiety or substance abuse/dependence disorders. Consideration should be given to the pathophysiology of the MDD, recognizing that current technology does not allow its identification in an individual patient. The pathophysiology must be considered in the selection of initial treatment; if an initial treatment has failed, treatment with a medication that has a different or expanded mechanism of action should be considered. Clinicians must also consider the importance of psychotherapy, where indicated, and listen to the feedback of their patients, tempering it with a measure of objectivity. Finally, clinicians must constantly query themselves as to whether there has been sufficient improvement in their patients with depression. It is the willingness to be appropriately aggressive in treating MDD that will ensure a timely, optimal outcome for their patients.
 ...
PMID:Remission as the goal of treatment in major depressive disorder. 1264 6

The objective of this study was to examine to what extent depressive symptoms are associated with reduced quality of life in schizophrenia by using a general population sample as control group. Patients with ICD-10 schizophrenia stabilized during hospitalization with antipsychotics were compared with a general population sample by use of self-reported scales for quality of life (the WHO Quality of Life Short Form, WHOQOL- BREF) and for depression (the Major Depression Inventory, MDI). Of the schizophrenic patients screened for ability to participate in the study, 40, or 71%, completed the two questionnaires as psychometrically valid as the control group. Within the group of schizophrenic patients, no association was seen with the types of antipsychotic medication prescribed (typical vs. atypical antipsychotics). Both in the group of schizophrenic patients and in the general population sample, those persons scoring on the MDI to have depressive symptoms had significant reduced quality of life. In conclusion, approximately 70% of the schizophrenic patients stabilized during hospitalization with antipsychotics are able to validly complete self-report scales measuring quality of life and depressive symptoms. In these patients, depressive symptoms, as in the general population, was found to have association with reduced quality of life.
 ...
PMID:Quality of life in schizophrenic patients: association with depressive symptoms. 1650 Jul 97

Executive function (EF) is increasingly recognized as being responsible for adverse developmental outcomes in preterm-born infants. Several perinatal factors may lead to poor EF development in infancy, and the deficits in EF can be identified in infants as young as eight months. A prospective cohort study was designed to study the EF in Chinese preterm infants and examine the relationship between EF in preterm infants and maternal factors during perinatal period. A total of 88 preterm infants and 88 full-term infants were followed from birth to eight months (corrected age). Cup Task and Planning Test was applied to assess the EF of infants, and the Bayley Scale of Infant Development (BSID-III) was used to evaluate cognitive (MDI) and motor abilities (PDI) of infants. In comparison with full-term infants, the preterm infants performed more poorly on all measures of EF including working memory, inhibition to prepotent responses, inhibition to distraction, and planning, and the differences remained after controlling the MDI and PDI. Anemia and selenium deficiency in mothers during pregnancy contributed to the differences in EF performance. However, maternal depression, hypertension, and diabetes during pregnancy were not related to the EF deficits in preterm infants. Future research should focus on the prevention of anemia and selenium deficiency during pregnancy and whether supplementing selenium in mothers during pregnancy can prevent further deterioration and the development of adverse outcomes of their offspring.
 ...
PMID:Comparison in executive function in Chinese preterm and full-term infants at eight months. 2862 14

A 91-year old female presented to Acute Medical Unit with a 2 week history of shortness of breath and haemoptysis. Her past medical history included osteoporosis, depression, irritable bowel syndrome, asthma, cataracts, and a colonic polypectomy. Her medications: Citalopram 10 mg, Co-codamol, Beclomethasone 200 mcg inhaler, Salbutamol MDI inhaler, Omeprazole 20 mg and Alendronic acid. She was an ex-smoker with a 20-pack year history who had stopped smoking 40-years ago. She did not drink alcohol and lived alone independently.
 ...
PMID:A Chest X-Ray causing confusion. 3112 1

Catatonia is characterized by motor and behavioral symptoms and can arise in a wide variety of medical and psychiatric conditions. We describe the case of a 16-year-old female with a history of anxiety and depression who presented with prominent symptoms of negativism, initially diagnosed as conversion disorder. She failed to respond to increasing doses of benzodiazepines; after over six weeks of hospitalization, she received electroconvulsive therapy (ECT), resulting in significant remission of symptoms. This case demonstrates the importance of prompt diagnosis and treatment of catatonia in adolescent patients, as well as the safety and efficacy of ECT in this population. Abbreviations: AACAP: American Academy of Child and Adolescent Psychiatry; BPAD: Bipolar affective disorder; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition; ECT: Electroconvulsive therapy; NMDA: N-methyl-D-aspartate.
 ...
PMID:Electroconvulsive therapy in an adolescent patient with catatonia: a case report. 3329 38


<< Previous 1 2